摘要
目的:观察大黄虫丸对肾纤维化血瘀证的临床疗效,扩大其临床适应证。方法:108例各类慢性肾小球肾炎患者,均经肾穿刺确诊,肾组织纤维化病理积分≥5分,以前瞻、随机、单盲、对照法分为治疗组72例,对照组36例,两组均予贝那普利和潘生丁口服,治疗组另予大黄虫丸口服,疗程为4个月。结果:两组治疗后Scr、24h尿蛋白定量、血清纤维连接蛋白(FN)、层黏连蛋白(LN)、血栓烷B2(TXB2)、纤溶酶原活化抑制剂(PAI)等水平的改变均较治疗前有明显好转(P<0.05),治疗组的血瘀证积分较治疗前及对照组差异都有统计学意义(P<0.01),治疗组BUN及TXB2的下降更为显著(P<0.05),治疗组的重复肾穿病例,其病理改变显著优于对照组的病例。结论:以上述方法控制肾纤维化进展的临床疗效确切,所检测指标和病理改变差异都有统计学意义,未发现明显毒副作用。
Objective：To investigate the effect of ＂Dahuang Zhechong Wan＂on blood stasis of kidney fibrosis,to extend its clinical usage. Methods： 108subjects diagnosed by renal biopsy were divided into treatment group （72 subjects） and control group （36 subjects）. Treatment group was treated by＂Dahuang Zhechong Wan＂, benazepril, persantin and control group was treated by benazepril and persantin for 4 months. Results：After treatment, in two groups those presenting a significant difference statistically are Scr, FN, LN, TXB2, and PAl. In treatment group, the clinical symptoms, BUN, and TXB2 and the pathological changes in the case of bi- biopsy have a remarkable improvement compared with control group. Conclusion：＂ Dahuang Zhechong Wan＂ combined with benazepril and persantin have a distinct effect on lightening kidney fibrosis without obvious side- effect.
出处
《中国中西医结合肾病杂志》
2009年第9期788-790,共3页
Chinese Journal of Integrated Traditional and Western Nephrology
基金
上海市卫生局基金资助项目(No.03-4067)
关键词
大黄虫丸
肾纤维化
血瘀证
肾穿刺
Dahuang zhechong wan
Kidney fibrosis
Blood stasis
Renal biopsy
